Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Harmonization Task Force

This article was originally published in RAJ Devices

Executive Summary

Update on study groups

Update on study groups

Following a series of meetings in the first half of 2004, study groups of the Global Harmonization Task Force (GHTF) have issued a number of guidance documents relating to basic regulatory practice in the medical device sector. These documents appear below, together with their reference numbers. The GHTF is a voluntary group of representatives from national medical device regulatory authorities and the regulated industry.

Study group 1

Study group1 (SG1) of the GHTF is responsible for comparing operational medical device regulatory systems around the world and identifying principles that may be suitable for harmonisation1. In addition, the group is responsible for developing a standardised format for premarket submissions and harmonised product labelling requirements. The next meeting of SG1 will be held in Portugal on 4-7 October 2004.

Table 1. GHTF study group 1 working items

Item

 

Reference

 

Status

 

Target for completion

 

Principles of Medical Devices Classification

 

SG1/N015

 

Proposed document comments awaited.

 

2004 / Q4

 

Principles of Conformity Assessment for Medical Devices

 

SG1/N040

 

Revised working draft to incorporate comments from

SG1 membership.

 

2005 / Q1

 

Summary Technical Documentation for Demonstrating Conformity to the

Essential Principles for Safety and Performance (STED)

 

SG1/N011

 

Proposed document comments

awaited.

 

2004 / Q4

 

Information Document Concerning the Definition of the Term ‘Medical Device’

 

SG1/N029

 

Proposed document - comments

awaited.

 

2004 / Q3

 

Labelling for Medical Devices - Revision of SG1/N009

 

SG1/N043

 

Latest draft being submitted to the steering committee as a

proposed document.

 

2005 / Q1

 

Essential Principles for Safety and Performance of Medical Devices -

Revision of SG1/N020

 

SG1/N041

 

Proposed document - comments

awaited.

 

2004 / Q3

 

Role of Standards in the Assessment of Medical Devices - Revision of

SG1/N012

 

SG1/N044

 

Proposed document - comments awaited.

 

2004 / Q4

 

Classification of In Vitro Diagnostic Devices

 

SG1/N045

 

Working draft to be circulated to SG1 shortly

 

2005 / Q1

 

Premarket Conformity Assessment for In Vitro Diagnostic Devices

 

SG1/N046

 

Subgroup preparing first draft

 

2004 / Q3

 

Study group 2

Study group 2 (SG2) reviews current adverse event reporting, postmarket surveillance and other forms of vigilance for medical devices to try and harmonise data collection and reporting systems. The next meeting of SG2 will be held in Vancouver on 27-29 September 2004.

Table 2. GHTF study group 2 working items

Item

 

Reference

 

Status

 

Target for completion

 

Comparison of the Device Adverse Reporting Systems in USA, Europe, Canada, Australia & Japan

 

SG2/ N6R3

 

NA

 

NA

 

Minimum Data Set for Manufacturer Reports to Competent Authority

 

SG2/ N7R1

 

NA

 

NA

 

Guidance on How to Handle Information Concerning Vigilance Reporting Related to Medical Devices

 

SG2/ N8R4

 

NA

 

NA

 

Global Medical Device Competent Authority Report

 

SG2/ N9R11

 

NA

 

NA

 

Precis - GHTF Study Group 2: Vigilance and Postmarket Surveillance

 

SG2/ N12R9

 

NA

 

NA

 

Charge & Mission Statement

 

SG2/ N16R5

 

NA

 

NA

 

Medical Devices: Post Market Surveillance: National Competent Authority Report Exchange Criteria

 

SG2/ N20R10

 

NA

 

NA

 

Adverse Event Reporting Guidance for the Medical Device Manufacturer or its Authorized Representative

 

SG2/ N21R8

 

NA

 

NA

 

Medical Device Postmarket Vigilance and Surveillance: Proposal for Reporting of Use Errors with Medical Devices by their Manufacturer or Authorized Representative

 

SG2/ N31R8

 

NA

 

NA

 

Medical Device Postmarket Vigilance and Surveillance: Universal Data Set for Manufacturer Adverse Event Reports

 

SG2/ N32R5

 

NA

 

NA

 

Medical Device Postmarket Vigilance and Surveillance: Timing of Adverse Event Reports

 

SG2/ N33R11

 

NA

 

NA

 

Manufacturer's Trend Reporting of Adverse Events

 

SG2/ N36R7

 

NA

 

NA

 

Review of Current Requirements on Postmarket Surveillance

 

SG2/N47R2.1

 

NA

 

NA

 

Medical Device Postmarket Vigilance and Surveillance: Application Requirements for Participation in the GHTF National Competent Authorities Report (NCARs) Exchange Programme

 

SG2/N38R11.2

 

NA

 

NA

 

Global Guidance for Adverse Event Reporting for Medical Devices

 

SG2/N54R2

 

NA

 

NA

 

Harmonisation of the Content of Advisory Notices and Recalls

 

SG2/N57R1

 

NA

 

NA

 

Study group 3

Study group 3 examines existing quality system requirements in countries with developed device regulatory systems and identifies areas suitable for harmonisation.

Table 3. GHTF study group 3 working items

Item

 

Reference

 

Status

 

Target for completion

 

Guidance on Quality Systems for the Design & Manufacturing of Medical Devices

 

SG3/ N99-8

 

NA

 

NA

 

Design Control Guidance for Medical Device Manufacturers

 

SG3/ N99-9

 

NA

 

NA

 

Quality Management Systems - Process Validation Guidance

 

SG3/ N99-10 (Edition 2)

 

NA

 

NA

 

SG3 Comments on ISO/DIS 13485 submitted to ISO TC 210 Working Group 1

 

SG3

 

NA

 

NA

 

Risk Management as an Integral Part of the Quality Management System

 

SG3/ N15R6

 

NA

 

NA

 

Study group 4

Study group 4 (SG4) examines quality system auditing practices (initially among the founding members of the GHTF) and develops guidance documents to harmonise the medical device auditing process. The next meeting of SG4 will be held in Canberra on 27-29 September 2004.

Table 4. GHTF study group 4 working items

Item

 

Reference

 

Status

 

Target for completion

 

Training Requirements for Auditors (Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers - Part 1: General Requirements - Supplement 2)

 

SG4/(00)3

 

NA

 

NA

 

Audit Language Requirements (Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers - Part 1: General Requirements - Supplement 1)

 

SG4/(99)14

 

NA

 

NA

 

Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers - Part 1: General Requirements

 

SG4/(99)28

 

NA

 

NA

 

Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers: General Requirements - Supplement No. 4 - Compilation of Audit Documentation (Clause 5.7)

 

SG4/N24R3

 

NA

 

NA

 

Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers General Requirements Supplement No. 6 Observed Audits of Conformity Assessment Bodies

 

SG4/N26R1

 

NA

 

NA

 

Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers - Part 2: Regulatory Auditing Strategy

 

SG4/N30R6

 

NA

 

NA

 

Guidelines for Regulatory Auditing of Quality Systems of Medical Device Manufacturers - Part 3: Regulatory Audit Reports

 

SG4/N33R4

 

NA

 

NA

 

References

1. GHTF website, www.ghtf.org

2. SG2 Phoenix meeting summary, www.ghtf.org

3. SG4 Tokyo meeting summary, www.ghtf.org

4. SG1 Canberra meeting summary, www.ghtf.org

Latest Headlines
See All
UsernamePublicRestriction

Register

SC093393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel